drugset / Trial / NCT04667910
601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to CRVO
Timeline
- Start
- 2021-01-27
- Primary completion
- 2022-11-16
- Completion
- 2022-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 601 | Monoclonal antibody | 1.25 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |